Decoding Drug Interactions: Character and Degree of Pharmacokinetic Interactions Between Telmisartan and Sorafenib or Donafenib in Rats by Li Y, Du W, Shan C, Yu Z, An J, Dong Z

Subjects: Get full text

Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Donafenib and Camrelizumab in the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Retr... by Wu C, Fu Z, Pan L, Li J, Zhou Y, Sun R, Gou Y, Zhao Y, Wang Z, Qiu Y, Huang P

Subjects: Get full text

Cooperative targeting of NF-κB enhances ferroptosis-driven HCC therapy with Alisertib and Donafenib by Qiong Zhou, Rui Wang

Subjects: Get full text

Triple Therapy with Interventional Treatment, Donafenib, and Anti-PD-1 Antibodies in Unresectable Hepatocellular Carcinoma: A Retrospective Real-World Study in China by Ye Q, Song Z, Yu T, Li Y, Ai L, Yang G, Su K, Chen D, Zhao W, Ding R, Zha Y, Li G

Subjects: Get full text

Investigation into the Use of Surufatinib and Donafenib as Novel Multi-Kinase Inhibitors Therapeutic Agents in Managing Advanced Differentiated Thyroid Cancer: A Systematic Review by Danut Dejeu, Paula Dejeu, Anita Muresan, Paula Bradea, Viorel Dejeu

Subjects: Get full text

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial by Xiaoyang Hong, Yongjian Guo, Wenbo Shi, Kangshun Zhu, Licong Liang, Liteng Lin, Ye Chen, Jingwen Zhou, Jingjun Huang, Jiabai Huang, Yaozhu Wu, Wensou Huang, Mingyue Cai

Subjects: Get full text